CONVERTIBLE DEBT |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CONVERTIBLE DEBT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CONVERTIBLE DEBT | NOTE 8. CONVERTIBLE DEBT
As of June 30, 2026, the Company has two series of convertible promissory notes outstanding under separate Securities Purchase Agreements entered into in 2023 and 2025, respectively. The aggregate outstanding principal of both series is $3,135,000, carried as a long-term liability on the Consolidated Balance Sheet. Each series is described separately below. All per share and conversion prices have been adjusted for the Reverse Stock Split (See Note 9).
2023 Notes
During October and November 2023, we entered into a Securities Purchase Agreement (the “2023 SPA”) with certain accredited investors (collectively, the “Investors”) pursuant to which we agreed to sell and issue to the Investors in a private placement transaction (the “Private Placement”) in one or more closings up to an aggregate principal amount of $5,000,000 of Convertible Notes (the “2023 Notes”). As of June 30, 2026, we had issued and sold an aggregate principal amount of $2,600,000 of 2023 Notes to certain Investors pursuant to the 2023 SPA, convertible into an aggregate of 693,334 shares of Common Stock at a conversion price of $3.75 per share.
The 2023 Notes mature and are due on the fifth anniversary of the issuance date in October and November of 2028. The 2023 Notes bear simple interest at a rate of 12% per annum, payable in equal monthly installments. The 2023 Notes are convertible into shares of our Common Stock at the option of the holder at a fixed conversion price of $3.75 per share. In addition, we may require the Investors to convert the 2023 Notes at the $3.75 per share conversion price at any time after 90 days from the issue date if the Common Stock has a closing bid price of $4.65 per share or higher on any twenty (20) trading days within a thirty (30) day consecutive trading period, or if a “fundamental change” occurs (as defined in the 2023 SPA). For the avoidance of doubt, $4.65 is the stock price threshold that triggers the Company’s mandatory conversion right and is not itself a conversion price; the notes always convert at $3.75 per share. The 2023 Notes are unsecured and senior to other indebtedness, subject to certain exceptions.
2025 Notes
During 2025, we entered into Securities Purchase Agreements (the “2025 SPA”) with certain accredited investors pursuant to which we agreed to sell and issue, in one or more closings, up to an aggregate principal amount of $3,000,000 of Convertible Notes (the “2025 Notes”). Pursuant to the 2025 SPA, and as adjusted for the Company’s 1-for-3 reverse stock split effective July 20, 2026, the Company had issued an aggregate principal amount of $535,000 of 2025 Notes as of June 30, 2026, initially convertible into an aggregate of 142,667 shares of Common Stock at a conversion price of $3.75 per share. Approximately $2,465,000 remained available for issuance under the 2025 SPA as of June 30, 2026, subject to its terms and conditions.
The 2025 Notes mature and are due on the fifth anniversary of the respective issuance dates in 2030. The 2025 Notes bear simple interest at a rate of 12% per annum, payable in equal monthly installments. The 2025 Notes are convertible into shares of our Common Stock at the option of the holder at a fixed conversion price of $3.75 per share. In addition, we may require the Investors to convert the 2025 Notes at the $3.75 per share conversion price at any time after 90 days from the issue date if the Common Stock has a closing bid price of $4.65 per share or higher on any twenty (20) trading days within a thirty (30) day consecutive trading period, or if a “fundamental change” occurs (as defined in the 2025 SPA). For the avoidance of doubt, $4.65 is the stock price threshold that triggers the Company’s mandatory conversion right and is not itself a conversion price; the notes always convert at $3.75 per share. The 2025 Notes are unsecured and senior to other indebtedness, subject to certain exceptions.
Interest expense on the 2023 Notes was $78,000 and $156,000 for each of the three and six months ended June 30, 2026 and 2025. Interest expense on the 2025 Notes was $16,050 and $32,100 for the three and six months ended June 30, 2026, respectively. Interest expense on the 2025 Notes was $10,225 and $13,075 for the three and six months ended June 30, 2025, respectively (reflecting partial-year accrual from the respective issuance dates).
Total interest expense on convertible notes for the three and six months ended June 30, 2026 was $94,050 and $188,100, respectively. Total interest expense on convertible notes for the three and six months ended June 30, 2025 was $88,225 and $169,075, respectively.
Registration Rights
In connection with each of the 2023 SPA and the 2025 SPA, we entered into registration rights agreements with the respective Investors pursuant to which we agreed to register for resale the shares of Common Stock issuable upon conversion of the respective Notes. As of June 30, 2026, we have not filed a resale registration statement covering these shares. We are evaluating the timing and method of fulfilling our registration obligations under each agreement. Failure to satisfy our registration obligations within the timeframes specified in the respective registration rights agreements could result in the payment of liquidated damages or other penalties to the Investors, the amount of which we are unable to estimate at this time.
Debt Issuance Costs and Interest
Amortization of deferred financing costs was $18,323 and $36,646 for the three and six months ended June 30, 2026, respectively (compared to $18,023 and $34,294 in the prior year), which have been included with interest expense on the statement of operations and is being amortized on a straight-line basis over the life of the notes. Annual cash interest payable on the aggregate outstanding principal of $3,135,000 at 12% per annum is approximately $376,200, payable in equal monthly installments.
Convertible notes consist of the following at:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||